Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Director · CEO and Interim CFO | March 14, 2017 | March 16, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Actinium Pharmaceuticals, Inc.
Report date March 14, 2017 · Filed March 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2027-03-14 | Direct | 250,000 |
Reported balance
After 2017-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-14 · Grant · Acquired 250,000 · Balance 250,000 F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 100,000 options are subject to cancellation based on the obtainment of certain milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 100,000 options are subject to cancellation based on the obtainment of certain milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2017 Filed Mar 16, 2017 22:18 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 250,000 | $1.39 Strike: $1.39 | $347,500.00 |
DisclosureSEC source: 0001213900-17-002501 · f4031417dave_actinium.xml · derivative · entry 1 DAVE KAUSHIK J · CIK 0001522751 · Director · CEO and Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 100,000 options are subject to cancellation based on the obtainment of certain milestones. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.